Crinetics Pharmaceuticals (CRNX) Projected to Post Earnings on Thursday

Crinetics Pharmaceuticals (NASDAQ:CRNX) is expected to be issuing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.22) per share and revenue of $8.5140 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its earnings results on Thursday, February 26th. The company reported ($1.29) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.08. The company had revenue of $6.16 million for the quarter, compared to the consensus estimate of $4.32 million. Crinetics Pharmaceuticals had a negative net margin of 6,046.22% and a negative return on equity of 41.46%. Crinetics Pharmaceuticals’s revenue was up NaN% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.88) EPS. On average, analysts expect Crinetics Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Crinetics Pharmaceuticals Trading Up 2.5%

NASDAQ CRNX opened at $42.29 on Tuesday. Crinetics Pharmaceuticals has a 12-month low of $25.83 and a 12-month high of $57.99. The company has a fifty day simple moving average of $38.52 and a two-hundred day simple moving average of $43.91. The stock has a market cap of $4.46 billion, a P/E ratio of -8.58 and a beta of 0.28.

Insider Activity

In other Crinetics Pharmaceuticals news, CFO Tobin Schilke sold 6,713 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $39.67, for a total value of $266,304.71. Following the sale, the chief financial officer directly owned 78,121 shares of the company’s stock, valued at approximately $3,099,060.07. This represents a 7.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Richard Scott Struthers sold 21,981 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $37.37, for a total value of $821,429.97. Following the sale, the chief executive officer directly owned 404,778 shares in the company, valued at $15,126,553.86. This represents a 5.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 142,380 shares of company stock valued at $5,569,475 over the last quarter. Insiders own 6.00% of the company’s stock.

Institutional Trading of Crinetics Pharmaceuticals

A number of hedge funds have recently modified their holdings of CRNX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Crinetics Pharmaceuticals by 11.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,311 shares of the company’s stock valued at $1,995,000 after acquiring an additional 6,148 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Crinetics Pharmaceuticals by 6.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company’s stock worth $11,658,000 after purchasing an additional 22,305 shares in the last quarter. Strs Ohio acquired a new stake in shares of Crinetics Pharmaceuticals during the 1st quarter worth approximately $124,000. Invesco Ltd. grew its stake in shares of Crinetics Pharmaceuticals by 11.7% during the 2nd quarter. Invesco Ltd. now owns 78,140 shares of the company’s stock worth $2,247,000 after purchasing an additional 8,181 shares during the period. Finally, Sei Investments Co. increased its holdings in shares of Crinetics Pharmaceuticals by 20.6% during the 2nd quarter. Sei Investments Co. now owns 60,180 shares of the company’s stock valued at $1,731,000 after purchasing an additional 10,269 shares in the last quarter. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research report on Monday, April 20th. Wall Street Zen cut Crinetics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Morgan Stanley increased their price objective on Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the company an “overweight” rating in a report on Tuesday, January 6th. Citizens Jmp raised their price objective on Crinetics Pharmaceuticals from $96.00 to $97.00 and gave the stock a “market outperform” rating in a research note on Tuesday, April 28th. Finally, Lifesci Capital raised Crinetics Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $76.75.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.